You are here: Industry Insights > Rakuten Medical

News List

FDA Accepts Rakuten Medical’s IND Application for Oncology Candidate contractpharma
December 17, 2021
Will begin clinical studies of RM-1995 photoimmunotherapy in advanced head and neck cancer.
Rakuten Medical Closes Deal with Merck KGaA, Darmstadt, Germany americanpharmaceuticalreview
July 16, 2020
Rakuten Medical announced they have entered a multi-year deal with Merck KGaA, Darmstadt, Germany under which Merck KGaA, Darmstadt, Germany will provide cetuximab to Rakuten Medical for its ASP-1929 program.
Rakuten Medical, MD Anderson Announce Collaboration to Advance Illuminox Platform americanpharmaceuticalreview
June 16, 2020
Rakuten Medical and The University of Texas MD Anderson Cancer Center (MD Anderson) announced a strategic alliance collaboration agreement to advance the development of new cancer therapies based on Rakuten Medical's proprietary Illuminox™ technology ...
Rakuten Medical reels in another megaround to fund cancer R&D fiercepharma
August 13, 2019
Rakuten Medical has raised $100 million to advance its pipeline of photoimmunotherapy oncology prospects. The biotech hopes to use antibodies and light to destroy cancer cells while leaving healthy tissues unharmed.
Rakuten Medical to further develop its photo-immunotherapy biospectrumasia
August 05, 2019
Photoimmunotherapy (PIT) is an investigational, anti-cancer treatment platform that is comprised of a drug and device combination that utilizes monoclonal antibodies conjugated to a dye
Japan approves Rakuten Medical's ASP-1929 to treat cancer biospectrumasia
April 10, 2019
ASP-1929 received Fast Track designation from the US Food and Drug Administration (FDA) for the treatment of head and neck squamous cell carcinomas (HNSCC) in the first quarter of 2018.
Rakuten Aspyrian changes name to Rakuten Medical biospectrumasia
March 04, 2019
This name more closely reflects the company's corporate purpose of creating a global biotechnology company integrating research and development with commercial operations.